Find News

Filter articles

Applied Filters

Showing 971 to 980 of 1033 results

C5 Forum on Biosimilars: the importance of regulation


At the 3rd C5 Forum on Biosimilars in London on Wednesday, a panel of lawyers and regulatory experts discussed the lie of the land for biosimilars.

Novartis takes on Roxane Laboratories over drug application


Novartis Pharmaceuticals has filed a lawsuit against US drug manufacturer Roxane Laboratories disputing an application for a schizophrenia drug.

India considering new patent filing rules


India is considering altering its requirements for filing drug patents in a bid to create more transparency in the pharmaceutical market, it has been claimed.

Teva to lose grip on Copaxone next year

US20-11-2013Legal developments

The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.

Senate IP counsel set for Covington switch


Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP.

Forest and Actavis settle over blood pressure drug


US pharmaceutical company Forest Laboratories and drug company Actavis have settled a legal dispute over a patent protecting blood pressure drug Bystoli (nebivolol).

SPC questions referred to CJEU in Actavis v Boehringer

EU, UK07-11-2013

The UK Patents Court has referred four questions to the CJEU seeking clarification on how the SPC Regulation should be interpreted in relation to drug products made of a combination of active ingredients.

Indian Patent Office rejects bid for cancer drug compulsory licence


The Indian Patent Office has rejected an application for a compulsory licence that was filed by domestic drug maker BDR Pharmaceuticals.

Arnold clears conflict of interest in SPC trial


Mr Justice Arnold has refused to recuse himself from a patent trial after he was accused of being conflicted by an expert witness.

Radcliffe leaves Mayer Brown for Charles Russell


Patent litigator Jonathan Radcliffe has left Mayer Brown to become partner at Charles Russell LLP.

Showing 971 to 980 of 1033 results